BioVendor Group Showcases Expanding Molecular Diagnostics Portfolio at ADLM 2026
BioVendor Group will present its growing portfolio of molecular diagnostic solutions at ADLM 2026, highlighting innovative technologies for oncology, newborn screening, inherited diseases, pharmacogenetics, and microbiome research.
The company's portfolio spans real-time PCR, reverse hybridization, and next-generation sequencing (NGS) technologies, providing laboratories with reliable, workflow-oriented solutions for precision medicine.
Among the featured technologies is the RealFast™ Assay portfolio, offering rapid real-time PCR solutions for newborn screening, pharmacogenetics, inherited diseases, and genetic predisposition. The portfolio includes assays for SCID-XLA, Spinal Muscular Atrophy (SMA), Cystic Fibrosis (CF), Sickle Cell Disease (SCD), Congenital Adrenal Hyperplasia (CAH), as well as a broad range of pharmacogenetic and cardiovascular markers.
BioVendor Group will also showcase its StripAssay® Portfolio, based on reverse hybridization technology for inherited diseases, pharmacogenetics, and genetic predisposition. The portfolio supports routine molecular diagnostics and confirmatory testing and includes solutions for Cystic Fibrosis, Thalassemia, hereditary haemochromatosis, HLA typing, and key pharmacogenetic markers including DPYD, CYP2D6, CYP2C19, and TPMT.
For solid tumor profiling, the company will present the epicGEN® Solid Cancer & MSI Kit, a hybrid capture NGS panel combining analysis of 44 clinically relevant cancer genes with 13 MSI markers. The assay is designed to support precision oncology through reliable detection of actionable biomarkers for diagnosis, prognosis, and treatment selection.
In hemato-oncology, BioVendor Group will introduce the fastGEN® Hemato-Oncology Portfolio, featuring amplicon-based NGS assays for rapid molecular profiling of hematological malignancies. With streamlined one-step library preparation and fast turnaround times, the portfolio supports AML, CML, and MPN testing, targeting clinically relevant biomarkers including BCR::ABL1, JAK2, CALR, MPL, TP53, and H3F3A/IDH1/2 for diagnosis, treatment selection, and disease monitoring.
Completing the NGS offering is the 16S Microbiome + ITS NGS Assay, an end-to-end solution for comprehensive microbiome profiling. By combining streamlined library preparation with integrated bioinformatic analysis, the assay enables simultaneous characterization of bacterial and fungal communities through analysis of the 16S rRNA and ITS2 regions, supporting a wide range of microbiome research applications.
"Our goal is to provide laboratories with practical, high-quality molecular diagnostic solutions that combine robust performance with streamlined workflows," said a BioVendor Group representative. "By expanding our portfolio across oncology, newborn screening, inherited diseases, pharmacogenetics, and microbiome research, we continue to support laboratories in delivering accurate and actionable molecular insights."
Visit BioVendor Group at ADLM 2026 to explore our latest innovations in molecular diagnostics and next-generation sequencing.